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Abstract 
Introduction 
There are limited data on the efficacy of early fluid resuscitation with third generation 
hydroxyethyl starch (HES 130) in burn injury. Adverse effects of HES on survival and organ 
function have been reported. 
Methods 
In this randomized, controlled, double-blind trial 48 patients with severe burn injury were 
assigned to receive either Lactated Ringer’s solution plus 6% HES 130/0.4 in a ratio of 2:1 or 
Lactated Ringer’s solution with no colloid supplement for the first 72 hours. Primary 
outcome parameter was the group difference of administered total fluid from intensive care 
unit (ICU) admission up to day 3. Secondary outcomes included kidney and lung injury and 
failure, length of stay, and mortality. 
Results 
3 days total of administered resuscitation fluid (medians) was 21,190 ml in the Lactated 
Ringer’s group and 19,535 ml in the HES group (HES: -1,213 ml; P = 0.39). Creatinine levels 
day 1 to 3 (HES: +0.4 µmol/l; 95% CI -18.7 to 19.5; P = 0.97) and urinary output day 1 to 3 
(HES: -58 ml; 95% CI −400 to 284; P = 0.90) were not different. 6 patients in each group 
developed acute respiratory distress syndrome (ARDS) (risk ratio 0.96; 95% CI 0.35 to 2.64; 
P = 0.95). Length of ICU stay (HES vs. Lactated Ringer’s: 28 vs. 24 days; P = 0.80) and 
length of hospital stay (31 vs. 29 days; P = 0.57) were similar. 28-day mortality was 4 
patients in each group (risk ratio 0.96; 95% CI 0.27 to 4.45; P = 0.95), in-hospital mortality 
was 8 in the HES group vs. 5 patients in the Lactated Ringer’s group (hazard ratio 1.86; 95% 
CI 0.56 to 6.19; P = 0.31). 
Conclusions 
There was no evidence that early fluid resuscitation with balanced HES 130/0.4 (6%) in 
addition to Lactated Ringer’s solution would lead to a volume sparing effect in severe burn 
injury. Together with the findings that early renal function, incidence of ARDS, length of 
stay, and mortality were not negatively influenced by HES in this setting, balanced HES 
130/0.4 (6%) plus Lactated Ringer’s solution could not be considered superior to Lactated 




There is an ongoing debate on fluid resuscitation in severe burn injury, especially for the first 
24 hours after trauma. Aggressive intravenous fluid therapy according to the Baxter formula 
is a mainstay of initial therapy. Multiple pathophysiological changes characterize the early 
posttraumatic phase. Massive systemic inflammation comparable to severe sepsis leads by the 
release of numerous mediators such as leukotrienes, prostaglandins and particularly 
histamine, in combination with complement activation products, to an extensive capillary 
leak [1,2]. Intravascular molecule and fluid shifts into the extravascular space cause severe 
hypovolemia and shock [3]. Changes in capillary membrane permeability also produce 
electrolytic alteration with intracellular sodium accumulation and consecutive cellular 
swelling [4]. Excessive tissue oedema, promoted to a large extent by the leakage of plasma 
proteins into the extravascular space normally occurs within the first few hours after trauma. 
The capillary leak is believed to resolve within 8 to 24 hours after trauma, but data vary [1,5]. 
In this critical situation of massive inflammation, hypovolemia and large oedema formation, 
it still remains unclear whether a “crystalloid only” therapy or a combination of crystalloids 
plus colloids should be used for volume resuscitation. Expert opinion consisted of strictly 
avoiding colloids such as hydroxyethyl starches (HES) during the first 24 hours [6]. This 
restriction was based on reports from the early 1970s expressing the fear of overloading the 
interstitial compartment with colloids in the early stage of trauma due to increased capillary 
leakage, thus leading to impaired wound healing after surgical treatment [7,8]. Although the 
Cochrane Injuries Group presented in 1998 a relative risk of death after albumin 
administration of 2.4 in a meta-analysis [9], human albumin is still used in burn aiming to 
reduce the fluid requirements for resuscitation [10,11] and tissue oedema. With the same 
intention different types of HES are frequently administered in burn injury, although safety 
and efficacy of HES products for fluid resuscitation is not fully evaluated and is intensely 
disputed especially during the last few years. However, we just recently have demonstrated in 
a prospective interventional open label study that hyperoncotic HES 200/0.5 (10%) might be 
associated with fatal outcome when used for early fluid resuscitation in severe burn injury 
[12]. A recent randomized controlled trial assigned 26 burn patients to either Hartmann’s 
solution plus HES 200/0.6 (6%) or to Hartmann’s solution only. The HES-supplemented fluid 
therapy led to significantly less fluid application than the Hartmann’s regimen and showed 
reduced interstitial oedema [13]. The least side effects on kidney function and coagulation is 
attributed to the third generation hydroxyethyl starches such as HES 130/0.4 (6%), but data 
on early fluid resuscitation in major burn with these modern starches are limited. 
We therefore addressed in this current RCT the question whether modern HES 130/0.4 (6%) 
administered within the first 24 hours after severe burn injury and up to 72 hours of treatment 
would be able to show any fluid sparing effect. 
(ClinicalTrials.gov number, NCT01012648) 
Materials and methods 
Trial design 
This study was an investigator-initiated, prospective, randomized, controlled, double-blind 
single-center trial. The study protocol was approved by the local ethical committee (KEK 4, 
Canton Zurich) and the Swiss Agency for Therapeutic Products (Swissmedic). Power 
calculation and planning of the statistical analysis was done at the Horten Centre for patient-
oriented research, University Hospital of Zurich. Reporting of the study was done according 
to the CONSORT guidelines. 
Participants 
All adults (age ≥ 16 yrs) with 2nd or 3rd degree acute burn injury and more than 15% of body 
surface area (BSA) burned who admitted to the University Hospital of Zurich burn unit 
between November 1, 2009 and January 31, 2013 were eligible for the study. All necessary 
written informed consent (deferred consent, if necessary, according to Swiss law HMG § 55 
and §56) was obtained from the patient or their legal surrogate within 24 hours after 
inclusion. In the case of written consent of the legal surrogate, all survivors gave written 
informed consent after recovery, which is in line with the local ethical committee regulations. 
Patients were excluded when they were expected to succumb within the next 24 to 36 hours, 
i.e. burn victims with whole body burn trauma, or in situations of palliative care, pregnancy, 
lack of informed consent, known allergy to HES, contraindications for balanced 6% HES 
130/0.4, intracerebral bleeding, acute renal failure, severe hypernatremia and other severe 
electrolyte disorders, severe von Willebrand Syndrome and acute liver failure. 
Study setting 
The study was performed in a tertiary burn unit at the university hospital of Zurich, 
Switzerland. The center is the larger of the two national burn units in Switzerland, running 6 
acute care beds. Approximately 80 severe burn victims are admitted to the university hospital 
per year. 
Interventions 
The primary study medication was balanced 6% HES 130/0.4. After patient enrollment and 
randomization, fluid resuscitation was done as follows. Each patient first received 2 bags of 
unblinded Lactated Ringer’s solution (500 ml each bag), followed by 1 bag (500 ml) of 
blinded study solution, the latter being either again Lactated Ringer’s solution or balanced 
6% HES 130/0.4. After each bag of study solution, all patients received again 2 bags of 
unblinded Lactated Ringer’s solution, before a next bag of study solution from the blinded 
box was infused. This fluid regimen alternating unblinded Lactated Ringer’s fluid with 
blinded study solution assured an overall ratio of crystalloids versus colloids of 2:1 in the 
HES patients. The patients not receiving HES but blinded Lactated Ringer’s study solution 
instead were exposed solely to crystalloids during the entire course of the study. Fluid 
resuscitation was guided by predefined target variables as listed in Figure 1 (see 
supplements). Accordingly, fluid administration was increased or decreased until target 
variables were reached. The administration of additional albumin or any other colloid was 
excluded in both the groups. All resuscitation fluids were administered as continuous 
infusions via peristaltic pumps. Infusion rate (ml/h) was continuously adjusted to the actual 
patient fluid needs. Except for volume resuscitation there was no difference in patient care 
including cardiovascular monitoring, pharmacologic and respiratory support, nutrition, and 
surgical treatment of burn wounds. 
Figure 1 MAP represents mean arterial pressure, ScvO2 central venous oxygen 
saturation, UO uriary output, Hct hematocrit, respectively. 
Outcome measures 
Primary outcome was the group difference of administered resuscitation fluid within the first 
72 hours after admission. Secondary endpoints were creatinine level at day 1 and the 
difference over day 1 to 3, urine output at day 1 and the difference over day 1 to 3, incidence 
of ARDS [14] during hospitalization, length of stay in the ICU, length of stay in the hospital, 
inhospital mortality, and 28-day mortality. Collected baseline characteristics were age, sex, 
systolic and diastolic blood pressure, heart rate, body weight, body height, percentage of 
burn, and the amount of prehospital administered fluids. 
A post-hoc analysis was performed for 90-day mortality and incidence of renal replacement 
therapy (RRT) during hospital stay. 
Sample size 
We based our sample size calculations on the primary outcome, which is the total volume of 
fluids given within the first 72 hours of treatment. We used data from our previous study with 
HES 200/0.5 [12] to estimate the average total volume of fluids given within the first 72 
hours of treatment with crystalloids (25 liters with crystalloid and 18 liters with HES) and to 
estimate its variability (standard deviation of around 12 and 7 liters, respectively). A sample 
size of 24 patients in each group allowed showing a difference of 25%, respectively in total 
volume of fluids given within the first 72 hours of treatment between the groups with a power 
of 80% at a significance level of 5% (two-sided). 
Blinding and randomization 
A third party not involved in the conduction (KAZ, Kantonsapotheke, Zürich) performed 
randomization and prepared the study solution, either balanced 6% HES 130/0.4 or Lactated 
Ringer’s solution, by sealing the identical 500 ml bags in black plastic foil concealing the 
product label and content. Thus, there was no possibility to recognize the fluid used. Bags 
were packed into boxes. 3 boxes of the same content labelled in consecutive order were 
assigned to each patient, one box for each 24 hours period up to 72 hours. For randomization, 
minimization was used with stratification for age (<or ≥50 years). Since minimization does 
not have a prespecified randomization list, concealment of random allocation was ensured. 
Thus, all patients were randomized double blind either to the Lactated Ringer’s plus balanced 
6% HES 130/0.4 group or to the Lactated Ringer’s only group, respectively, and study 
medication was assigned to the patients. To make sure, that there was no overload of 6% HES 
130/0.4 study medication, the maximum amount (for HES according to the manufacturer’s 
manual 50 ml per kg BW per 24 hours) was calculated based on the estimated body weight at 
study enrollment. A body weight of 80 kg e.g. led to 4′000 ml of study solution, which 
resulted in 8 bags of 500 ml each of blinded solution. Not more than that was brought to the 
patient. 
Statistical methods 
We included all patients in the analysis according to the group they were randomized to. To 
compare the outcomes between the two groups we used linear regression analysis for 
continuous outcomes (e.g. fluids), logistic regression for binary outcomes (e.g. ARDS) and 
Cox proportional hazard regression for in-hospital mortality, always with group allocation as 
independent variable. To compare the total volume of fluids given within the first three days 
after randomization, creatinine values, and urinary output over the first 72 hours, we used a 
random effects model that took the auto-correlated structure of repeated measurements 
(measurement on first, second and third day) into consideration (xtreg command of STATA). 
All analyses were conducted using STATA (STATA for Windows, version 10.2, Stata Corp; 
College Station, TX). 
Results 
Participants 
From November 1, 2009 through January, 31 2013, 159 patients were assessed for inclusion 
into the study, 111 patients were not eligible. From the enrolled 48 patients, 23 patients were 
assigned to receive Lactated Ringer’s solution plus balanced 6% HES 130/0.4 (HES group) 
and 23 to receive Lactated Ringer’s solution (Lactated Ringer’s group). 2 patients had to be 
excluded from the study because they retrospectively did not fulfill inclusion criteria (1 
primarily included patient with negative pregnancy test had to be excluded secondarily 
because of revised pregnancy test to positive shortly thereafter. 1 patient was initially 
assessed 20% deep burned area but showed less than 15% intraoperatively). 1 patient was lost 
for analysis in the Lactated Ringer’s group because of early discharge within less than <72 
hours from the ICU. This patient was formally not excluded, but no study data were available 
for incorporation into the statistics. Participant flow is shown in Figure 2. Baseline 
characteristics were well balanced between groups (Table 1). 
Figure 2 Study Flow Diagram. 
Table 1 Baseline characteristics of the patients 
Characteristic HES Lactated Ringer’s 
 (N = 23) (N = 22) 
Age (yrs) 49 (22, 69) 47 (26, 61) 
Sex (male) 17 (73.9%) 17 (77.2%) 
Systolic blood pressure (mmHg) 109 (93, 130) 123 (104, 150) 
Diastolic blood pressure (mmHg) 60 (55, 65) 68 (59, 76) 
Heart rate (beats/min) 83 (70, 95) 86 (75, 95) 
Weight (kg) 75 (70, 83) 80 (70, 80) 
Height (cm) 175 (170, 180) 176 (170, 180) 
Burned TBSA (%) 31 (21, 47) 32 (20, 50) 
Data are represented as median (25th and 75th percentile) or median (percent). None of the differences between 
the two groups were significant (P > 0.05). 
Two patients were excluded although randomized because did not fulfill inclusion criteria and 1 patient was not 
excluded formally but was not in analyses because of lack of data. 
TBSA represents total body surface area. 
Fluid therapy 
During the pre-hospital phase the Lactated Ringer’s group received a median of 1′800 ml and 
the HES group 2′000 ml of fluid, respectively (difference not significant); no colloids were 
administered. Calculated fluid requirement for the first 24 hours based on the Baxter formula 
was not different between the 2 groups (Lactated Ringer’s group: 8′520 vs. HES: 9′000 ml). 
The median 3 days total of effectively administered fluid was 21′190 ml in the Lactated 
Ringer’s group vs. 19′535 ml in the HES group. A median amount of 5′650 ml of HES was 
administered in the colloid group, no HES was administered in the Lactated Ringer’s group 
(details see Table 2). 
  
Table 2 Fluid therapy 
Variable HES Lactated Ringer’s 
 (N = 23) (N = 22) 
Prehospital crystalloids (ml) 2000 (1000, 2500) 1800 (1000, 3600) 
Prehospital colloids (ml) 0 (0, 0) 0 (0, 0) 
Baxter formula (ml) 9000 (5880, 13536) 8520 (7920, 18080) 
Total fluids day 1 (ml) 10050 (6700, 16800) 11575 (9300, 19770) 
Total fluids day 2 (ml) 5500 (3750, 8825) 5025 (3180, 9300) 
Total fluids day 3 (ml) 3340 (2060, 7000) 4150 (1640, 6100) 
Total fluids days 1–3 (ml) 19535 (13820, 29770) 21190 (14760, 33960) 
Total crystalloids days 1–3 (ml) 13200 (10075, 19020) 21190 (14760, 33960) 
Total colloids days 1–3 (ml) 5650 (3745, 9000) 0 (0, 0) 
Data are represented as median (25th and 75th percentile). 
Outcomes 
Regarding the primary endpoint there was a group difference in fluids given over the first 72 
hours of -1′213 ml in the HES group, which was not statistically significant (95% CI -3′975 
to 1′549; p = 0.39). With regard to secondary outcomes there was no difference over the first 
72 hours in creatinine levels (+0.4 µmol/l; 95% CI -18.7 to 19.5; p = 0.97) and in urinary 
output (-58 ml; 95% CI −400 to 283; p = 0.90). The incidence of ARDS was 6 patients in 
each group (risk ratio 0.96; 95% CI 0.35 to 2.64; p = 0.95) and there was again no difference 
in length of ICU stay and hospital stay (28 vs. 24 days; p = 0.80 and 31 vs. 29 days; p = 
0.57), respectively. 28-day mortality was 4 patients in each group (risk ratio 0.96; 95% CI 
0.27 to 4.45; p = 0.95) and in-hospital mortality was 8 in the HES group vs. 5 in the Lactated 
Ringer’s group (hazard ratio 1.86; 95% CI 0.56 to 6.19; p = 0.31), see Table 3. 
  
Table 3 Primary and secondary outcomes 
Outcome HES Lactated Ringer’s Difference P value 
(N = 23) (N = 22) 
Primary outcome     
Total volume days 1–3 (ml)   −1213 (95%CI −3975 to 
1549) 
0.39 
Secondary outcomes     
Creatinine day 1 (µmol/l) 77 (66, 99) 74 (55, 90)   
Creatinine days 1–3 (µmol/l)   0.4 (95% CI −18.7 to 19.5) 0.97 
Urinary output day 1 (ml/d) 1360 (1020, 1770) 1430 (970, 2225)   
Urinary output days 1–3 (ml)   −58 (95% CI −400 to 283) 0.90 
Incidence ARDS 6 (26.1%) 6 (27.3%)   
Risk ratio for ARDS with HES   0.96 (95% CI 0.35 to 2.64) 0.95 
28-day mortality 4 (17.4%) 4 (18.2%)   
Risk ratio for 28-day mortality with 
HES 
  0.96 (95% CI 0.27 to 4.45) 0.95 
In hospital mortality 8 (34.8%) 5 (22.7%)   
Hazard ratio for in-hospital death 
with HES 
  1.86 (95% CI 0.56 to 6.19) 0.31 
Length of stay ICU (days) 28 (10, 58) 24 (11, 49)  0.80 
Length of stay hospital (days) 31 (18, 58) 29 (14, 61)  0.57 
Data are represented as median (25th and 75th percentile) or number of patients (percent) or risk ratio 
(confidence interval) or hazard ratios (confidence interval). For total volume, creatinine, and urinary output over 
days 1–3, absolute values with original units (confidence interval) are depicted. 
The results of the post-hoc analysis of 90-day mortality and incidence of renal replacement 
therapy showed no difference between the groups. Data are depicted in Table 4. 
Table 4 Post-hoc analysis 90-day mortality and need for renal replacement therapy 
(RRT) 
Outcome (post-hoc analysis) HES Lactated Ringer’s Difference P value 
(N = 23) (N = 22) 
90-day mortality 8 (34.8%) 6 (27.3%)   
Risk ratio for 90-day mortality with HES   1.27 (95% CI 0.51 to 3.26) 0.59 
Need for RRT 6 (26.1%) 6 (27.3%)   
Risk ratio for need of RRT with HES   0.96 (95% CI 0.35 to 2.64) 0.95 
Data are represented as number of patients (percent) or risk ratio (confidence interval). 
Discussion 
In this randomized, controlled trial no fluid saving effect was detected by the use of balanced 
6% HES 130/0.4 as compared to Lactated Ringer’s solution alone in patients with severe 
burn injury. Furthermore, early renal function as determined by serum creatinine levels, 
development of ARDS, length of ICU and hospital stay, in-hospital and 28-day mortality 
were not different between treatment groups. 
In severe burn injury with massive systemic inflammation comparable to severe sepsis, 
aggressive fluid resuscitation to maintain hemodynamic stability and stable kidney function is 
pivotal. The most widely accepted formula to estimate fluid requirements in burns is the 
Baxter formula, which is, however, rather underestimating the volume needed in about half of 
the patients [15-17]. The downside of significant fluid load in burned patients might be 
accentuated oedema formation and thus impaired wound healing after surgical treatment. 
Hence, a reduction of fluid load especially during the first 24 to 48 hours, where the most 
resuscitation volume is needed, appears to be desirable in order to improve surgical outcome. 
The role of hydroxyethyl starch in various clinical settings remains controversial. A possible 
volume sparing effect, assigned to colloids in general, is the main indication for its 
widespread use, although the extent of fluid load reduction may be overestimated. There is 
only few data about the use of hydroxyethyl starch in patients with burn injury. Vlachou et al. 
showed in a recent randomized controlled trial in burned patients a clear volume sparing 
effect and furthermore reduced oedema formation with HES 200/0.6 (6%) supplementation 
[14]. However, as reported by our group, older generation HES such as the hyperoncotic HES 
200/0.6 (10%) might be associated with higher incidence of renal failure and higher overall 
mortality in severe burn injury [12]. One explanation could be related to the fact, that only 
about 33 to 66% of the administered hyperoncotic HES is excreted in the urine in the first 24 
hours after infusion [18]. Thus, the remaining HES molecules, which are still in high 
concentration, may circulate for a long time and a substantial proportion might accumulate in 
various tissues including kidney. Hyperoncotic HES deposition was demonstrated in dogs by 
histopathology in intravascular and interstitial spaces of various organs including proximal 
renal tubular cells, thus possibly inducing renal failure [19]. There are also many case studies 
describing acute deterioration of preexisting renal impairment after the administration of 
hyperoncotic HES [20,21]. 
Very limited data are available on modern third generation hydroxyethyl starches such as 
HES 130 in burns. Only one small randomized open label study reported more favourable 
parameters related to the extent of tissue oedema and a reduced mortality with HES 130/0.4 
[13]. With regard to kidney function, James et al. just recently demonstrated in penetrating 
trauma patients resuscitated with HES 130/0.4 a better lactate clearance and less acute kidney 
injury than in patients treated with saline [22]. Furthermore, Boussekey and colleagues 
showed in a observational retrospective study in 363 ICU patients no difference in acute 
kidney injury after the use of HES 130/0.4 as compared to crystalloids [23]. These findings, 
not necessarily connecting the administration of HES 130/0.4 to acute renal failure, are 
supporting our current data showing no increasing creatinine levels over the first 3 days of 
fluid resuscitation with HES 130. However, it has to be mentioned, that in our study HES 130 
was co-infused together with Lactated Ringer’s solution in a ratio of 2:1, which might be 
protecting the kidney from acute deterioration and failure. In large contrast, several recent 
trials and analyses not focusing on burn injury have drawn different conclusions with regard 
to kidney failure. Although an improvement of sublingual microcirculation after resuscitation 
with HES 130/0.4 versus saline was reported [24], septic patients receiving HES 130 were 
more likely to developing acute kidney injury, requiring renal replacement therapy, and being 
at increased risk of death after 90 days [17,25]. This is in line with the findings in a large 
multicentre trial where it was shown in 7′000 patients that the application of HES 130/0.4 
resulted in more adverse events and more renal replacement therapies as compared to patients 
receiving 0.9% saline for fluid resuscitation [26]. Taken this recent large studies and meta-
analyses together, HES products including HES 130 preparations might be associated with 
increased mortality and acute kidney injury in ICU patients [27-32]. Whether this data can 
ultimately be translated to burn injury needs further investigation. 
The current study has several limitations: firstly, the application of resuscitation fluids was 
algorithm based and conducted by different individuals of our ICU staff. Nevertheless, over 
two years of study duration, this effect has probably been levelled out over time. Secondly, 
the used volume resuscitation algorithm was very traditional and did not include any 
hemodynamic measurement tools such as pulmonary artery catheter or PiCCO. Only clinical 
signs and various hemodynamic and surrogate parameters (mean arterial pressure, central 
venous oxygen saturation, urinary output, hematocrit) were used to guide volume therapy. 
The reason for this simplified approach comes on the one hand from our clinical experience 
with fluid therapy in burned patients suggesting that this approach is reliable, and on the other 
hand from the lack of clear evidence for better fluid therapy by the use of advanced 
hemodynamic guidance tools. Our data show that estimated fluid requirements for the first 24 
hours (calculated with the Baxter formula) is comparable with the effectively infused amount 
of resuscitation fluid in both the HES and the crystalloid group. And as known from the 
literature, the Baxter formula rather underestimates the necessary amount of infusion fluid 
[15-17], which was the case in our study as well. Thirdly, power calculation was done to 
detect a potential volume sparing effect, but not to determine differences in mortality, organ 
failure and length of stay. The latter are secondary endpoints, for which the study is 
underpowered due to the relatively small sample size. Therefore, differences in mortality, 
organ failure and length of stay have to be interpreted with caution. 
The strength of the study is it’s randomized, double blinded and controlled design making the 
findings reliable and of clinical relevance. An implication for further research would be the 
initiation of randomized controlled trials with large sample sizes to strengthen the current 
evidence of a missing volume sparing effect of modern hydroxyethyl starches in burn injury. 
With regard to safety concerns that have arisen after the latest metaanalysis reporting a 
significant risk for mortality and acute kidney injury in various patient groups [28], further 
studies should specifically address this issue in burned patients. 
Conclusions 
This randomized, controlled, double-blind study did not provide any evidence that early fluid 
resuscitation with balanced HES 130/0.4 (6%) as an add-on fluid to Lactated Ringer’s 
solution during the first 72 hours after burn injury would lead to a volume sparing effect. 
Together with the findings that early renal function, incidence of ARDS, length of stay, and 
mortality were not negatively influenced by HES in this setting, balanced HES 130/0.4 (6%) 
plus Lactated Ringer’s solution could not be considered superior to Lactated Ringer’s 
solution alone. 
Key messages 
• All patients received more resuscitation fluid than Baxter formula suggested. 
• The use of balanced 6% HES 130/0.4 did not result in reduced fluid requirement in severe 
burn victims. 
• There is no advantage of using 6% HES 130/0.4 in severe burn injury. 
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MAP < 60 mmHg
Continue fluid resuscitation, when :
ScvO2 < 65%









• If the points 2 to 4 are fulfilled, but not point 1,
start vasopressor therapy.
• If the points 1 to 4 are fulfilled, reduce fluid resuscitationFigure 2
